HOME >> BIOLOGY >> NEWS
REMICADE Phase 3 data show rapid, significant, long-term psoriasis improvement

, data was analyzed from the REMICADE 5 mg/kg every eight week maintenance arm of each trial, the only regimen common to both EXPRESS and EXPRESS II. At week 10, after infusions at weeks 0, 2, and 6, the proportions of patients achieving PASI 75 were 80 percent versus three percent of placebo patients for EXPRESS and 75 percent versus two percent of placebo patients for EXPRESS II, (both P < 0.001 versus placebo). At week 10, the proportions of patients achieving PASI 90, or nearly complete skin clearance, were 57 percent versus one percent of placebo patients for EXPRESS and 45 percent versus 0.5 percent of placebo patients for EXPRESS II, (both P < 0.001 versus placebo). PASI 75 responses achieved at week 10 were maintained through week 26 in both EXPRESS and EXPRESS II (81 percent and 78 percent of patients achieved at least PASI 75 improvement from baseline, respectively), and the majority of patients achieved PASI 75 at week 50 in the REMICADE 5 mg/kg every eight-week maintenance groups.

"These data show great potential for REMICADE in the treatment of a disease that often carries great physical and emotional challenges," said Robert Matheson, MD, Oregon Medical Research Center, and study investigator. "The potential of achieving nearly complete skin clearance is exciting and holds great promise for patients with this difficult to treat disease."

Investigators reported that at week 10 patients in both EXPRESS and EXPRESS II receiving REMICADE experienced improvements in the Dermatology Life Quality Index (DLQI) and Physician's Global Assessment (PGA), measures of quality of life and psoriasis severity, respectively. In both studies, following 5 mg/kg induction therapy, REMICADE-treated patients experienced a median improvement of nine points in DLQI, a change that is considered to be a clinically meaningful decrease in psoriasis-related burden for the patient, compared to no improvement for placebo patients (REMICADE vs. placebo, -9.0 ve
'"/>

Contact: Michael Parks
215-983-8000
Centocor, Inc.
3-Mar-2006


Page: 1 2 3

Related biology news :

1. Data in New England Journal of Medicine show benefits of REMICADE in ulcerative colitis patients
2. Active psoriatic arthritis patients on REMICADE achieve major clinical response in arthritis
3. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
4. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
5. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
6. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
7. Phase III trials of cellulose sulfate microbicide for HIV prevention closed
8. Phylonix awarded National Science Foundation Phase II SBIR for zebrafish screening
9. Kentucky first state to match federal SBIR-STTR Phase 1 and Phase 2 grants
10. Acorda announces positive Phase 3 Fampridine-SR study in people with multiple sclerosis
11. New Phase 3 data show potential benefits of Aranesp dosed every three weeks for CIA

Post Your Comments:
(Date:10/18/2014)... a sample of patients with undiagnosed, suspected genetic conditions, ... with a higher molecular diagnostic yield than traditional molecular ... JAMA . The study is being released to coincide ... , Exome sequencing, which sequences the protein­coding region of ... material present in a cell or organism), has been ...
(Date:10/17/2014)... in German . ... day in order to reproduce? And why are there two ... the latest issue of the research journal Molecular Human ... Steven Ramm from Bielefeld University Bielefeld has compiled this special ... for a female to copulate with several males in quick ...
(Date:10/17/2014)... German . ... When treating overdoses, doctors are often limited to supportive therapy ... is a combination of drugs involved. So what can be ... grandmother,s pills? ETH professor Jean-Christophe Leroux from the Institute of ... to this question. "The task was to develop an agent ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... OncLive® is pleased ... at Thomas Jefferson University has joined its Strategic ... Alliance Partnership program, the Sidney Kimmel Cancer Center ... awareness of the Center’s cutting-edge research programs, comprehensive ... and other health care professionals from the Sidney ...
(Date:10/19/2014)... , Oct. 19, 2014 NextCODE Health, which enables ... genome in real time, today announced the launch of its ... Exchange , at the American Society of Human Genetics (ASHG) ... learn more, sign up and apply for free beta access, ... features and benefits can be viewed here . ...
(Date:10/19/2014)... 19, 2014 The Asian Orthopedic braces and ... Asia with analysis and forecast of revenue. The Orthopedic braces ... to around $416.5 million by 2018, at a developing CAGR ... TOC of the Asian Orthopedic braces and support systems market, ... also provides a glimpse of the segmentation of orthopedic braces ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4
Cached News: